# US 2022/0025374 A1 · Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025374 A1
- Document ID: US20220025374A1
- Status: Published application
- Kind: A1
- Application number: 16/961,062
- Filed: 2019-01-11
- Published: 2022-01-27
- Earliest claimed: 2018-01-12
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Paulo Martins; Xiaofei E.; Timothy Kowalik
- Web page: https://patentgrep.com/patent/US20220025374A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for treating ischemia (such as ischemia repertusion injury (IRI)) in tissue (such as transplant donor tissue), comprising contacting the tissue during ex vivo perfusion with a therapeutically effective amount of RNAi (such as siRNA) that specifically hinds to at least a portion of a gene (such as p53) that mediates ischemic injury in the tissue. The invention's methods additionally decrease the risk of tissue rejection and/or or induce immunological tolerance to transplanted tissue.

## Claims

### Claim 1

A method for treating ischemia in a target tissue, comprising contacting the tissue, during ex vivo perfusion of the tissue, with a therapeutically effective amount of RNAi sequence that specifically binds to at least a portion of a gene that mediates ischemic injury in the tissue, thereby producing a treated tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein one or both of the target tissue and the treated tissue is disconnected from a mammalian subject's circulatory system.

### Claim 3 (depends on 1)

The method of claim 1, wherein the contacting is prior to transplanting the treated tissue to a mammalian recipient.

### Claim 4 (depends on 3)

The method of claim 3, wherein further comprising the step of transplanting the treated tissue into a transplant recipient.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ischemic injury comprises apoptosis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ischemic injury comprises inflammation.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ischemic injury comprises neutrophil infiltration.

### Claim 8 (depends on 1)

The method of claim 1, wherein the gene is selected from the group consisting of apoptotic gene, inflammatory gene, complement gene, major complex antigen gene, autophagy gene and Toll like receptor gene.

### Claim 9 (depends on 8)

The method of claim 8, wherein the apoptotic gene comprises p53 gene.

### Claim 10 (depends on 1)

The method of claim 1, wherein said RNAi comprises siRNA.

### Claim 11 (depends on 10)

The method of claim 10, wherein said siRfNA comprises p53 gene siRNA.

### Claim 12 (depends on 11)

The method of claim 11, wherein said p53 gene siRNA comprises an RNA sequence that specifically binds with mRNA encoded by p53 gene sequence 5′-GCATGAACCGAGGCCCAT-3′ (SEQ ID NO: 1) or by the complement thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein said p53 gene siRNA comprises one or both of p53 sense siRNA 5′-r(GCAUGAACCGAGGCCCAU)dTdT-' (SEQ ID NO: 2) and p53 antisense 5′-r(AUGGGCCUCGGUUCAUGC)dTdT-3′ (SEQ ID NO: 3).

### Claim 14 (depends on 1)

The method of claim 1, wherein the perfusion is selected from the group consisting of normothermic perfusion, sub-normothermic perfusion, and hypothermic perfusion.

### Claim 15 (depends on 1)

The method of claim 1, wherein the target tissue comprises liver tissue.

### Claim 16 (depends on 8)

The method of claim 8, wherein the apopmtic gene comprises a FAS receptor gene.

### Claim 17 (depends on 16)

The method of claim 16, wherein said RNAi sequence comprises an siRNA sequence that specifically binds with mRNA encoded by one or more of FAS receptor gene sequences 5′-GCAGGCCAAGTTGCTGAAT-3′ (SEQ ID NO: 4), 5′-GGCCAAGTTGCTGAATCAA-3′ (SEQ ID NO: 5). 5′-GCCAAGTTGCTGAATCAAT-3′ (SEQ ID NO: 6), 5′-TCGTGAGCTCGTCTCTGAT-3′ (SEQ ID NO: 7), and 5′-CCCGCGCCAGGCCAAGIT-3′ (SEQ ED NO: 8), or with the complement of any thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein said FAS receptor gene siRNA comprises one or both of FAS receptor gene sense siRNA and antisense siRNA.

### Claim 19 (depends on 18)

The method of claim 18, wherein said FAS receptor gene sense siRNA comprises one or more of 5′-GUGCAAGUGCAAACCAGACdTdT-3′ (SEQ ID NO: 9) 5′AGCCGAAUGUCGCAGAACCdTdT-3′(SEQ ID NO: 10), 5′-GGAUUAUAUCAAGGAGGCCdT-3′(SEQ. ID NO: 11), 5′-AUCGCCUAUGGUUGUUGACdTdT-3′ (SEQ ID NO: 12), 5′-AUACAUCCCGAGAAUUGCUdTdT-3′ (SEQ ID NO: 13), and 5′-AAGCCGAAUGUCGCAGAACdTdT-3′ (SEQ ID NO: 14).

### Claim 20 (depends on 19)

The method of claim 19, wherein said FAS receptor gene sense siRNA comprises 5′-GUGCAAGUGCAAACCAGACdTdT-3′ (SEQ ID NO: 9).

### Claim 21 (depends on 18)

The method of claim 18, wherein said FAS receptor gene antisense siRNA comprises one or more of 5′-GUCUGGUUUGCACUUGCACdTdT-3′ (SEQ ID NO: 15), 5′-GUUCUGCGACAUUCGGCUdTdT-3′(SEQ ID NO: 21), 5′-GGCCUCCUUGAUAUAAUCCdTdT-3′ (SEQ ID NO: 16), 5′-GUCAACAACCAUAGGCGAUdTdT-3′ (SEQ ID NO: 17), 5′-AGCAAUUCUCGGGAUGUAUdTdT-3′ (SEQ ID NO: 18), and 5′-GUUCUGCGACAUUCGGCUUdTdT-3′ (SEQ ID NO: 19).

### Claim 22 (depends on 21)

The method of claim 21, wherein said FAS receptor gene antisense siRNA comprises 5′-GUCUGGUUUGCACUUGCACdTdTCy3-3′ (SEQ ID NO: 20).

### Claim 23 (depends on 1)

The method of claim 1, wherein said contacting comprises a normothermic temperature.

### Claim 24 (depends on 1)

The method of claim 1, wherein said contacting comprises a hypothermic temperature.

### Claim 25 (depends on 1)

The method of claim 1, wherein said contacting comprises a sub-normothermic temperature.

### Claim 26

A method for reducing injury in a target tissue, comprising perfusing the tissue in the presence of siRNA that reduces gene expression of a gene hat causes ischemic injury in the tissue, thereby reducing; injury and producing a treated tissue.
